Perceptive Advisors LLC Lowers Stake in Sionna Therapeutics, Inc. $SION

Perceptive Advisors LLC lessened its stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 44.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 658,439 shares of the company’s stock after selling 520,659 shares during the quarter. Perceptive Advisors LLC’s holdings in Sionna Therapeutics were worth $26,397,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in SION. Goldman Sachs Group Inc. bought a new position in shares of Sionna Therapeutics in the 1st quarter worth $667,000. Woodline Partners LP bought a new stake in Sionna Therapeutics during the first quarter valued at about $837,000. Geode Capital Management LLC boosted its position in Sionna Therapeutics by 113.4% during the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after purchasing an additional 153,712 shares in the last quarter. Rhumbline Advisers purchased a new position in Sionna Therapeutics in the second quarter valued at about $307,000. Finally, New York State Common Retirement Fund purchased a new position in Sionna Therapeutics in the second quarter valued at about $118,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on SION. BTIG Research reissued a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. Wedbush started coverage on shares of Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective on the stock. Citizens Jmp reiterated a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Stifel Nicolaus increased their target price on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, May 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $53.22.

Insider Transactions at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 989,630 shares of company stock worth $44,987,483 in the last 90 days. Insiders own 5.10% of the company’s stock.

Sionna Therapeutics Price Performance

Shares of SION stock opened at $47.13 on Friday. Sionna Therapeutics, Inc. has a 1-year low of $16.38 and a 1-year high of $51.56. The stock’s fifty day moving average price is $41.66 and its 200 day moving average price is $40.02. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -24.42 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.